Institutional shares held 6.41 Million
4.5K calls
400 puts
Total value of holdings $37.2M
$26K calls
$2K puts
Market Cap $89.8M
16,260,400 Shares Out.
Institutional ownership 39.4%
# of Institutions 38


Latest Institutional Activity in XGN

Top Purchases

Q3 2024
Stonepine Capital Management, LLC Shares Held: 534K ($2.95M)
Q3 2024
Kennedy Capital Management, Inc. Shares Held: 170K ($936K)
Q3 2024
Renaissance Technologies LLC Shares Held: 176K ($969K)
Q3 2024
Creative Planning Shares Held: 35.5K ($196K)
Q3 2024
Ubs Group Ag Shares Held: 78.5K ($433K)

Top Sells

Q3 2024
Wasatch Advisors Inc Shares Held: 490K ($2.71M)
Q3 2024
Perkins Capital Management Inc Shares Held: 459K ($2.53M)
Q3 2024
Penbrook Management LLC Shares Held: 63K ($348K)
Q3 2024
Tower Research Capital LLC (Trc) Shares Held: 1.31K ($7.24K)
Q3 2024
Silvercrest Asset Management Group LLC Shares Held: 541K ($2.99M)

About XGN

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.


Insider Transactions at XGN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
572K Shares
From 5 Insiders
Grant, award, or other acquisition 485K shares
Open market or private purchase 87K shares
Sell / Disposition
220K Shares
From 2 Insiders
Open market or private sale 220K shares

Track Institutional and Insider Activities on XGN

Follow EXAGEN INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XGN shares.

Notify only if

Insider Trading

Get notified when an Exagen Inc. insider buys or sells XGN shares.

Notify only if

News

Receive news related to EXAGEN INC.

Track Activities on XGN